fda sued over tirzepatide backtracks Eli Lilly weight-loss drug shortage FDA approves Zepbound for obstructive

Epub 2025 Oct 9

one year after stopping both the medication and the lifestyle intervention, they had regained a mean of two-thirds of their prior weight loss

Situations requiring healthcare provider consultation: Frequent dose timing inconsistencies that suggest adherence challenges Concurrent illness affecting medication absorption or tolerance Addition of new medications that may interact with tirzepatide Persistent or worsening gastrointestinal symptoms Any uncertainty about appropriate dose timing Patients should be aware that tirzepatide may reduce the effectiveness of oral hormonal contraceptives due to delayed gastric emptying

Studies show that meal sequence the order foods are eaten in can impact GLP-1